Prevalência e fatores sociodemográficos associados ao óbito por câncer de ovário em um município do interior de Minas Gerais, Brasil, 2013-2024
##plugins.themes.bootstrap3.article.sidebar##
Publicado
May 3, 2025
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Investigar a prevalência do óbito e fatores sociodemográficos de pacientes diagnosticadas com câncer de ovário no município de Barbacena, Minas Gerais. Métodos: Estudo observacional transversal e descritivo-analítico, no qual foram utilizados dados de prontuários médicos de pacientes com câncer de ovário atendidas no serviço de oncologia de um hospital do interior de Minas Gerais, no Campo das Vertentes. Resultados: Foram analisados 125 prontuários de mulheres com câncer de ovário, com média de idade de 60,9 anos. A taxa de óbito foi de 46,4%, sendo maior entre pacientes de 31 a 59 anos (50,0%) do que entre 60 e 93 anos (43,7%). Houve redução nos óbitos entre 2018 e 2021. Estado civil, tabagismo e histórico familiar foram associados a maior risco de óbito, mas apenas o histórico familiar manteve-se significativo na análise multivariada. Conclusão: O estudo demonstrou uma taxa de óbito alta (46,4%) para o câncer de ovário, destacando a gravidade da doença e a necessidade de diagnóstico precoce. Analisou fatores como estado civil sem companheiro, tabagismo e história familiar de câncer sem informação mostraram associação com a mortalidade, sendo que o último se manteve altamente significativo.
##plugins.themes.bootstrap3.article.details##
Como Citar
SáF. F. de, CarvalhoF. L. F. de, SciaviccoM. G., LemosN. da S. de, SciaviccoP. G., PuiattiT. K. A., DizJ. B. M., & FariaF. C. (2025). Prevalência e fatores sociodemográficos associados ao óbito por câncer de ovário em um município do interior de Minas Gerais, Brasil, 2013-2024. Revista Eletrônica Acervo Saúde, 25(5), e20586. https://doi.org/10.25248/reas.e20586.2025
Seção
Artigos Originais
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. BRASIL. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Relatório de Recomendação Nº150- Diretrizes e Terapêuticas de Neoplasias maligna epitelial de ovário. 2019.
2. DANGELO J, FATTINI C. Anatomia Humana Sistêmica e Segmentar. 3rd ed. SP: Atheneu, 2007, 780p.
3. DERCHAIN SFM, et al. Panorama atual e perspectivas em relação ao diagnóstico precoce do câncer de ovário. Revista Brasileira de Ginecologia e Obstetrícia, 2009; 31(4): 159–163.
4. EASTON DF, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet., 1995; 56(1): 265-71.
5. FERRAZ VEF, et al. How the gynecologist can guide women with a family history of cancer? Rev. Bras. Ginecol. Obstet., 2014; 36(8).
6. FRIEBEL TM, et al. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst., 2014; 106: 6.
7. GAONA-LUVIANO P. Epidemiology of ovarian cancer. Chinese clinical oncology, 2020; 9(4).
8. GRAM IT, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. International Journal of Cancer, 2012; 130(9): 2204-2210.
9. HARRIS HR, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology and Prevention Biomarkers, 2018; 27(2): 174-182.
10. HE ZX, et al. Predictive factors of ovarian carcinoma for women with ovarian endometrioma aged 45 years and older in China. Journal of ovarian research, 2017; 10(1): 1-8.
11. HELDER-WOOLDERINK JM, et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer., 2016; 55: 65-73.
12. HUANG T, et al. Depression and risk of epithelial ovarian cancer: results from two large prospective cohort studies. Gynecologic oncology, 2015, v. 139, n. 3, p. 481-486.
13. INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa da incidência e mortalidade por câncer no Brasil 1999. Rio de Janeiro: INCA / Conprev.
14. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) monographs on the evaluation of carcinogenic risks to humans, volume 91, Combined Estrogen-Progestogen contraceptives and combined Estrogen Progestogen menopausal therapy: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2005, 7 - 14 June.
15. KANG Y, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research, 2016; 22(7): 1713-1724.
16. KIM HS, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British Journal of Cancer, 2014; 110(7): 1878-1890.
17. KURMAN RJ, SHIH LM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol., 2010; 34(3): 433-43.
18. MEIRA KC, et al. Efeitos da idade-período e coorte na mortalidade por câncer do ovário no Brasil e suas grandes regiões. Cadernos de Saúde Pública, 2019; 35(3): e00087018.
19. PINOTTI JA, et al. Tratado de Ginecologia. Rio de Janeiro: Revinter; 2005; 792-8: 833-7.
20. MOMENIMOVAHED Z, et al. Ovarian cancer in the world: epidemiology and risk factors. International journal of women’s health, 2019; 11: 287.
21. MORGAN RD, et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Jornal Med Genet., 2019; 0: 1–7.
22. POOLE EM, et al. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes & Control, 2016, 27(5): 661-668.
23. RASMUSSEN CB, et al. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiology and Prevention Biomarkers, 2017; 26(1): 104-109.
24. REIS FJC dos. Rastreamento e diagnóstico das neoplasias de ovário: papel dos marcadores tumorais. Revista Brasileira de Ginecologia e Obstetrícia, 2005; 27(4): 222–227.
25. RIBEIRO CM, et al. Efeitos de curto prazo da pandemia de COVID-19 na realização de procedimentos de rastreamento, investigação diagnóstica e tratamento do câncer no Brasil: estudo descritivo, 2019-2020. Scielo Brasil. Epidemiol. Serv. Saúde, 2022; 31(1).
26. ROBERTS AL, et al. Posttraumatic Stress Disorder Is Associated with Increased Risk of Ovarian Cancer: A Prospective and Retrospective Longitudinal Cohort Study. Cancer research, 2019; 79(19): 5113-5120.
27. SILVA-FILHO AL, et al. Cirurgia não ginecológica em pacientes com câncer de ovário. Rev Bras Ginecol Obstet., 2004; 26(5): 411-6.
28. SOEGAARD M, et al. Risk of ovarian cancer in women with first-degree relatives with cancer. Alta Obstetricia et Gynecologica Scandinavica, 2009; 88(4): 449-456.
29. STRUEWING JP, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med., 1997; 336(20): 1401-8
30. TEIXEIRA N, et al. The association between cancer family history and ovarian cancer risk in BRCA ½ mutation carries: can it be explained by the mutation position?. European Journal of Human Genetics, 2018; 26: 848–857.
31. TITUS-ERNSTOFF L, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer, 2001; 84(5): 714-21.
32. TORRES JCC, et al. Risk-of-Malignancy Index in preoperative evaluation of clinically restricted ovarian cancer. Sao Paulo Med J., 2002; 120(3): 72-6.
33. TRUDEL-FITZGERALD C, et al. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosomatic medicine, 2019; 81(9): 833-840.
34. USSET JL, et al. Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Epidemiology and Prevention Biomarkers, 2016; 25(5): 780-790.
35. ZHANG Y, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC cancer, 2019; 19(1): 1-14.
36. WALKER M, et al. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ, 2019; 191(32): 886-893.
2. DANGELO J, FATTINI C. Anatomia Humana Sistêmica e Segmentar. 3rd ed. SP: Atheneu, 2007, 780p.
3. DERCHAIN SFM, et al. Panorama atual e perspectivas em relação ao diagnóstico precoce do câncer de ovário. Revista Brasileira de Ginecologia e Obstetrícia, 2009; 31(4): 159–163.
4. EASTON DF, et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet., 1995; 56(1): 265-71.
5. FERRAZ VEF, et al. How the gynecologist can guide women with a family history of cancer? Rev. Bras. Ginecol. Obstet., 2014; 36(8).
6. FRIEBEL TM, et al. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst., 2014; 106: 6.
7. GAONA-LUVIANO P. Epidemiology of ovarian cancer. Chinese clinical oncology, 2020; 9(4).
8. GRAM IT, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. International Journal of Cancer, 2012; 130(9): 2204-2210.
9. HARRIS HR, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology and Prevention Biomarkers, 2018; 27(2): 174-182.
10. HE ZX, et al. Predictive factors of ovarian carcinoma for women with ovarian endometrioma aged 45 years and older in China. Journal of ovarian research, 2017; 10(1): 1-8.
11. HELDER-WOOLDERINK JM, et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer., 2016; 55: 65-73.
12. HUANG T, et al. Depression and risk of epithelial ovarian cancer: results from two large prospective cohort studies. Gynecologic oncology, 2015, v. 139, n. 3, p. 481-486.
13. INSTITUTO NACIONAL DE CÂNCER (INCA). Estimativa da incidência e mortalidade por câncer no Brasil 1999. Rio de Janeiro: INCA / Conprev.
14. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) monographs on the evaluation of carcinogenic risks to humans, volume 91, Combined Estrogen-Progestogen contraceptives and combined Estrogen Progestogen menopausal therapy: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2005, 7 - 14 June.
15. KANG Y, et al. Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clinical Cancer Research, 2016; 22(7): 1713-1724.
16. KIM HS, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British Journal of Cancer, 2014; 110(7): 1878-1890.
17. KURMAN RJ, SHIH LM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol., 2010; 34(3): 433-43.
18. MEIRA KC, et al. Efeitos da idade-período e coorte na mortalidade por câncer do ovário no Brasil e suas grandes regiões. Cadernos de Saúde Pública, 2019; 35(3): e00087018.
19. PINOTTI JA, et al. Tratado de Ginecologia. Rio de Janeiro: Revinter; 2005; 792-8: 833-7.
20. MOMENIMOVAHED Z, et al. Ovarian cancer in the world: epidemiology and risk factors. International journal of women’s health, 2019; 11: 287.
21. MORGAN RD, et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Jornal Med Genet., 2019; 0: 1–7.
22. POOLE EM, et al. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes & Control, 2016, 27(5): 661-668.
23. RASMUSSEN CB, et al. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiology and Prevention Biomarkers, 2017; 26(1): 104-109.
24. REIS FJC dos. Rastreamento e diagnóstico das neoplasias de ovário: papel dos marcadores tumorais. Revista Brasileira de Ginecologia e Obstetrícia, 2005; 27(4): 222–227.
25. RIBEIRO CM, et al. Efeitos de curto prazo da pandemia de COVID-19 na realização de procedimentos de rastreamento, investigação diagnóstica e tratamento do câncer no Brasil: estudo descritivo, 2019-2020. Scielo Brasil. Epidemiol. Serv. Saúde, 2022; 31(1).
26. ROBERTS AL, et al. Posttraumatic Stress Disorder Is Associated with Increased Risk of Ovarian Cancer: A Prospective and Retrospective Longitudinal Cohort Study. Cancer research, 2019; 79(19): 5113-5120.
27. SILVA-FILHO AL, et al. Cirurgia não ginecológica em pacientes com câncer de ovário. Rev Bras Ginecol Obstet., 2004; 26(5): 411-6.
28. SOEGAARD M, et al. Risk of ovarian cancer in women with first-degree relatives with cancer. Alta Obstetricia et Gynecologica Scandinavica, 2009; 88(4): 449-456.
29. STRUEWING JP, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med., 1997; 336(20): 1401-8
30. TEIXEIRA N, et al. The association between cancer family history and ovarian cancer risk in BRCA ½ mutation carries: can it be explained by the mutation position?. European Journal of Human Genetics, 2018; 26: 848–857.
31. TITUS-ERNSTOFF L, et al. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer, 2001; 84(5): 714-21.
32. TORRES JCC, et al. Risk-of-Malignancy Index in preoperative evaluation of clinically restricted ovarian cancer. Sao Paulo Med J., 2002; 120(3): 72-6.
33. TRUDEL-FITZGERALD C, et al. Social integration, marital status, and ovarian cancer risk: A 20-year prospective cohort study. Psychosomatic medicine, 2019; 81(9): 833-840.
34. USSET JL, et al. Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Epidemiology and Prevention Biomarkers, 2016; 25(5): 780-790.
35. ZHANG Y, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC cancer, 2019; 19(1): 1-14.
36. WALKER M, et al. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ, 2019; 191(32): 886-893.